Joseph Meletiadis

List of Publications by Citations

149 papers	6,132 citations	36 h-index	75 g-index
156 ext. papers	7,406 ext. citations	6.4 avg, IF	5.49 L-index

#	Paper	IF	Citations
149	Infections caused by Scedosporium spp. *Clinical Microbiology Reviews*, **2008**, 21, 157-97	34	497
148	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infectious Diseases, The*, **2019**, 19, e405-e421	25.5	441
147	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clinical Microbiology and Infection*, **2014**, 20 Suppl 3, 5-26	9.5	413
146	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. *Clinical Microbiology and Infection*, **2014**, 20 Suppl 3, 27-46	9.5	291
145	In vitro susceptibilities of zygomycetes to conventional and new antifungals. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 45-52	5.1	246
144	Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. *Emerging Infectious Diseases*, **2015**, 21, 1041-4	10.2	238
143	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. *Clinical Microbiology and Infection*, **2014**, 20 Suppl 3, 47-75	9.5	207
142	In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 62-8	5.9	205
141	In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 106-17	5.9	204
140	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. *Journal of Clinical Microbiology*, **2000**, 38, 2949-54	9.7	175
139	Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 609-16	5.9	173
138	Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	148
137	Colorimetric assay for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 3402-8	9.7	142
136	Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. *American Journal of Clinical Pathology*, **2007**, 127, 349-55	1.9	118
135	In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 470-2	5.9	88
134	Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. *Journal of Infectious Diseases*, **2006**, 194, 1008-18	7	84
133	Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 2382-94	5.9	81

132	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. *Medical Mycology*, **2005**, 43, 133-52	3.9	80
131	In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 470-8	5.1	78
130	EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. *Clinical Microbiology and Infection*, **2016**, 22, 571.e1-4	9.5	78
129	Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3329-37	5.9	73
128	In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7735-42	5.9	68
127	Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 321-8	5.9	68
126	Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 4256-63	9.7	67
125	Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1097-105	5.9	64
124	Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2053-64	5.9	52
123	Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2002**, 40, 2876-85	9.7	49
122	Azole-Resistance in and Related Species: An Emerging Problem or a Rare Phenomenon?. *Frontiers in Microbiology*, **2018**, 9, 516	5.7	46
121	Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. *Journal of Antimicrobial Chemotherapy*, **2006**, 58, 1168-76	5.1	44
120	Use of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive Candidiasis. *Journal of Clinical Microbiology*, **2006**, 44, 143-50	9.7	44
119	In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 953-5	5.1	43
118	Rapid susceptibility testing of medically important zygomycetes by XTT assay. *Journal of Clinical Microbiology*, **2006**, 44, 553-60	9.7	43
117	Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 881-7	5.9	43
116	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. *Clinical Microbiology and Infection*, **2019**, 25, 681-687	9.5	42
115	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2374-2379	5.1	42

114	Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. *Journal of Clinical Microbiology*, **2011**, 49, 2722-7	9.7	37
113	Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 403-10	5.9	35
112	In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6934-7	5.9	34
111	Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 343-8	5.1	34
110	Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. *Journal of Medical Microbiology*, **2004**, 53, 129-134	3.2	34
109	Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2524-9	5.9	33
108	A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. *Clinical Microbiology and Infection*, **2017**, 23, 776.e1-776.e5	9.5	32
107	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3325-3333	5.1	32
106	In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 796-803	5.9	32
105	Human pharmacogenomic variations and their implications for antifungal efficacy. *Clinical Microbiology Reviews*, **2006**, 19, 763-87	34	31
104	Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. *Medical Mycology*, **2007**, 45, 513-8	3.9	29
103	Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. *Journal of Clinical Microbiology*, **2003**, 41, 4718-25	9.7	29
102	Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2196-204	5.9	26
101	The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. *International Journal of Antimicrobial Agents*, **2006**, 28, 439-49	14.3	26
100	Rare Invasive Fungal Infections: Epidemiology, Diagnosis and Management. *Current Fungal Infection Reports*, **2013**, 7, 351-360	1.4	24
99	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *Journal of Hematology and Oncology*, **2021**, 14, 168	22.4	24
98	Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	23
97	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1611-9	5.1	23

96	Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4656-63	5.9	23
95	Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 230-7	5.1	23
94	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 709-719	5.1	21
93	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. *International Journal of Antimicrobial Agents*, **2019**, 53, 34-39	14.3	21
92	The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1738-44	5.9	20
91	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3374-3381	5.1	19
90	Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. *Clinical Microbiology and Infection*, **2018**, 24, 1200-1204	9.5	18
89	Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1625-31	5.9	18
88	Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. *Pharmacogenomics*, **2008**, 9, 561-84	2.6	18
87	Molecular detection and identification of enteroviruses in children admitted to a university hospital in Greece. *Molecular and Cellular Probes*, **2011**, 25, 249-54	3.3	17
86	Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	17
85	Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins. *Journal of Clinical Microbiology*, **2017**, 55, 1714-1719	9.7	16
84	Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3973-83	5.9	16
83	Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 953-961	5.1	16
82	Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3135-3147	5.1	16
81	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	16
80	Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. *PLoS ONE*, **2013**, 8, e72280	3.7	16
79	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1807-1819	5.1	16

78	How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. *Clinical Microbiology and Infection*, **2021**, 27, 55-60	9.5	16
77	Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
76	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. *Lancet Infectious Diseases, The*, **2021**, 21, e375-e386	25.5	15
75	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2883-9	5.1	14
74	Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2356-62	5.9	14
73	In vitro combination therapy with isavuconazole against Candida spp. *Medical Mycology*, **2017**, 55, 859-868	3.9	13
72	Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. *International Journal of Antimicrobial Agents*, **2015**, 45, 670-1	14.3	13
71	Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus. *Clinical Microbiology and Infection*, **2017**, 23, 98-103	9.5	13
70	Manogepix (APX001A) Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	13
69	EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6432-6	5.9	12
68	Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. *Mycoses*, **2010**, 53, 239-45	5.2	12
67	Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19. *Infectious Diseases and Therapy*, **2020**, 9, 707-713	6.2	12
66	Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach. *Journal of Pharmaceutical Sciences*, **2016**, 105, 1513-8	3.9	12
65	Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6173-8	5.9	11
64	Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 632-6	5.9	11
63	Rhodotorula mucilaginosa associacted meningitis: A subacute entity with high mortality. Case report and review. *Medical Mycology Case Reports*, **2014**, 6, 46-50	1.7	11
62	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. *Reviews in Medical Microbiology*, **2002**, 13, 101-117	1.1	11
61	Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	10

60	Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7367-73	5.9	10
59	In vitro activity of CAY-1, a saponin from Capsicum frutescens, against Microsporum and Trichophyton species. *Medical Mycology*, **2008**, 46, 805-10	3.9	10
58	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 988-996	5.1	10
57	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3366-3373	5.1	9
56	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
55	Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications. *Journal of Medical Microbiology*, **2016**, 65, 211-218	3.2	9
54	Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations. *Journal of Fungi (Basel, Switzerland)*, **2018**, 4,	5.6	8
53	Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5923-9	5.9	8
52	Relationship between metabolism and biomass of medically important zygomycetes. *Medical Mycology*, **2006**, 44, 429-38	3.9	8
51	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against : the Importance of Heteroresistance for Growth Outcome. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
50	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 387-394	5.1	8
49	Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1879-1888	5.1	7
48	Genetic diversity and antifungal susceptibility patterns of Aspergillus nidulans complex obtained from clinical and environmental sources. *Mycoses*, **2020**, 63, 78-88	5.2	7
47	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. *Infectious Diseases and Therapy*, **2021**, 10, 1779-1792	6.2	7
46	Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis. *Journal of Thoracic Disease*, **2016**, 8, E312-6	2.6	7
45	Characterization and outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the FungiScope registry and literature reports. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 765-774	5.1	7
44	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1761-1762	5.1	6
43	A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1799-1806	5.1	6

42	Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 3713-8	5.9	6
41	Near-infrared spectroscopy of the urinary bladder during voiding in men with lower urinary tract symptoms: a preliminary study. *BioMed Research International*, **2013**, 2013, 452857	3	6
40	MixInYeast: A Multicenter Study on Mixed Yeast Infections. *Journal of Fungi (Basel, Switzerland)*, **2020**, 7,	5.6	6
39	Experimental Candida albicans osteomyelitis: Microbiologic, antigenic, histologic, and 18FDG-PET-CT imaging characteristics in a newly established rabbit model. *Medical Mycology*, **2019**, 57, 1011-1017	3.9	6
38	Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips. *Journal of Clinical Microbiology*, **2015**, 53, 3654-9	9.7	5
37	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 172-180	5.1	5
36	Nationwide surveillance of azole-resistant Aspergillus fumigatus environmental isolates in Greece: detection of pan-azole resistance associated with the TR46/Y121F/T289A cyp51A mutation. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 3181-3188	5.1	5
35	Molecular Epidemiology and Antifungal Susceptibility of Isolates in Greece: Emergence of Terbinafine-Resistant Type VIII Locally and Globally. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	5
34	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 634-5	5.1	4
33	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2247-2254	5.1	4
32	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. *Clinical Microbiology and Infection*, **2020**, 26, 1692-1693	9.5	4
31	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an Pharmacokinetic-Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
30	In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. *International Journal of Antimicrobial Agents*, **2021**, 58, 106440	14.3	4
29	and Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
28	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, C and D in Antimicrobial Resistance of Complex in Clinical Isolates. *Microbial Drug Resistance*, **2020**, 26, 1144-1152	2.9	3
27	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. *Journal of Microbiological Methods*, **2020**, 171, 105861	2.8	3
26	Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy* , **2020**, 75, 140-148	5.1	3
25	Comparative pharmacokinetics of the three echinocandins in ICU patients. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2969-2976	5.1	3

24	Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in Checkerboard Assays. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
23	Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin. *Medical Mycology Case Reports*, **2016**, 12, 24-7	1.7	3
22	Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. *British Journal of Clinical Pharmacology*, **2021**, 87, 1024-1032	3.8	3
21	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020** , 64,	5.9	2
20	Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for Antifungal Susceptibility Testing of Cryptococcus neoformans. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
19	Evaluation of paper gradient concentration strips for antifungal combination testing of Candida spp. *Mycoses*, **2015**, 58, 679-87	5.2	2
18	Fungal malignant otitis externa caused by Alternaria chlamydospora: first case report. *JMM Case Reports*, **2015**, 2,	0.5	2
17	Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	2
16	Antimicrobial pharmacokinetics and preclinical models to support optimized treatment approaches for uncomplicated lower urinary tract infections. *Expert Review of Anti-Infective Therapy*, **2021**, 19, 271-295	5.5	2
15	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. *International Journal of Antimicrobial Agents*, **2021**, 57, 106291	14.3	2
14	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3201-3211	5.1	2
13	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. *Antibiotics*, **2022**, 11, 771	4.9	2
12	Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2573-2581	5.1	1
11	A New Marker of Echinocandin Activity in an Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	1
10	Bacterial quantification in tissue homogenates from pharmacodynamic studies using growth curves. *Journal of Medical Microbiology*, **2020**, 69, 676-684	3.2	1
9	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. *Journal of Pharmacy and Pharmacology*, **2020**, 72, 1750-1760	4.8	1
8	Performance, Correlation and Kinetic Profile of Circulating Serum Fungal Biomarkers of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	1
7	Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 511-513	4.4	1

6	A Prospective Multicenter Cohort Surveillance Study of Invasive Aspergillosis in Patients with Hematologic Malignancies in Greece: Impact of the Revised EORTC/MSGERC 2020 Criteria. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	1
5	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes.. *Journal of Antimicrobial Chemotherapy*, **2022**,	5.1	0
4	Fungemia due to Moesziomyces aphidis (Pseudozyma aphidis) in a premature neonate. Challenges in species identification and antifungal susceptibility testing of rare yeasts.. *Journal De Mycologie Medicale*, **2022**, 32, 101258	3	0
3	In‐vitro and in‐vivo study on the effect of antifungal agents on hematopoietic cells in mice. *Experimental Biology and Medicine*, **2015**, 240, 1728-34	3.7	
2	Reply to "Agar Bioassays for Antifungals in Combination Therapy". *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5626	5.9	
1	Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation. *Blood*, **2019**, 134, 4498-4498	2.2	